{"abstract":"The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/03/06/2017-04229.html","cfr_references":[],"citation":"82 FR 12611","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The public meeting will be held on May 4, 2017, from 1 p.m. to 5 p.m. Registration to attend the meeting must be received by April 24, 2017 (see SUPPLEMENTARY INFORMATION for instructions). Submit either electronic or written comments on the public meeting by July 5, 2017. Late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 5, 2017. The https:// www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of July 5, 2016. Comments received by mail/hand delivery/courier (for written paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. See the SUPPLEMENTARY INFORMATION section for registration date and information.","disposition_notes":null,"docket_ids":["Docket No. FDA-2017-N-0136"],"dockets":[],"document_number":"2017-04229","effective_on":null,"end_page":12613,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/03/06/2017-04229.xml","html_url":"https://www.federalregister.gov/documents/2017/03/06/2017-04229/public-meeting-on-patient-focused-drug-development-for-autism-request-for-comments","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-04229?publication_date=2017-03-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-03-06/2017-04229/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":1883,"last_updated":"2026-09-23 00:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-03-06/pdf/2017-04229.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-04229.pdf?1488548757","publication_date":"2017-03-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/03/06/2017-04229.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"Exhibit D Letters from Individual Consumers / Health Professionals re: Letter from Eckert Seamans to FDA DDM","document_id":"FDA-2017-N-0136-0045"},{"title":"Exhibit B Letters from Individual Consumers / Health Professionals re: Letter from Eckert Seamans to FDA DDM","document_id":"FDA-2017-N-0136-0044"},{"title":"Attachment 4 Testimony of Marie Washington Hearing before The Honorable Katherine Field June 24, 2016 re: Comment from The Judge Rotenberg Educational Center, Inc. (Eckert Seamans)","document_id":"FDA-2017-N-0136-0042"},{"title":"Attachment 3 Testimony of Mitchell Shear Hearing before The Honorable Katherine Field May 23, 2016 re: Comment from The Judge Rotenberg Educational Center, Inc. (Eckert Seamans)","document_id":"FDA-2017-N-0136-0041"},{"title":"Attachment 2 Testimony of Paul Peterson Hearing before The Honorable Katherine Field June 13, 2016 re: Comment from The Judge Rotenberg Educational Center, Inc. (Eckert Seamans)","document_id":"FDA-2017-N-0136-0040"},{"title":"Attachment 1 Testimony of Lauren Emmick Hearing before The Honorable Katherine Field May 24, 2016 re: Comment from The Judge Rotenberg Educational Center, Inc. (Eckert Seamans)","document_id":"FDA-2017-N-0136-0039"}],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2017-N-0136","supporting_documents_count":6,"docket_id":"FDA-2017-N-0136","regulation_id_number":null,"title":"Public Meeting on Patient-Focused Drug Development for Autism","checked_regulationsdotgov_at":"2017-05-26T12:00:26Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":12611,"subtype":null,"title":"Public Meeting on Patient-Focused Drug Development for Autism; Request for Comments","toc_doc":"Patient-Focused Drug Development for Autism","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":82}